ResearchMoz

Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits

GBI Research
Published Date » 2012-06-25
No. Of Pages » 60
 GBI Research, the leading business intelligence provider, has released its new report Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits. It analyzes the overall Supply Chain Management (SCM) scenario and provides profiles of the leading participants in the pharmaceutical supply chain in the US. The report is built using data and information sourced from proprietary databases, as well as primary and secondary research and in-house analysis by GBI Researchs team of industry experts.  The top three wholesalers in the US, AmerisourceBergen Corporation, Cardinal Health and McKesson Corporation, accounted for 86.7% of the overall US pharmaceutical market in 2011 and combined revenue of $295.2 billion. Various supply chain models are...
Table of Contents

1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Executive Summary
2.1 Global Pharmaceutical Companies Changing View of Supply Chain as a Major Driver to Improve Margins and Increase Revenue Growth
2.2 Anti-counterfeiting Technologies such as Radio Frequency Identification to Limit the Introduction of Fake Drugs into the Supply Chain
2.3 Cold-chain Storage to Play Critical Role in the Future Pharmaceutical Supply Chain

3 Pharmaceutical Supply Chain in the US – Introduction
3.1 Report Guidance

4 Pharmaceutical Supply Chain in the US – Introductory Issues
4.1 Evolution of Supply Chain Management
4.2 The Pharmaceutical Supply Chain – Operational Issues
4.2.1 Demand Management with Adequate Forecast Tools to Reduce Inventory Levels
4.2.2 Optimum Inventory Levels Help to Maintain Flow of Working Capital
4.2.3 Supply Chain Performance Visibility in Pharmaceutical Supply Chain Management
4.3 Key Uncertainties in Production Planning and Scheduling
4.3.1 Forecasting Managers have to Deal with the Uncertainty in Demand for Existing Drugs
4.3.2 Uncertainties Experienced by Pipeline Drugs
4.4 Different Supply Chains in Pharmaceutical Industry
4.5 Reverse Logistics Evolving as a Significant Part of the Pharmaceutical Supply Chain
4.6 High Costs Due to Drug Callbacks
4.6.1 Recall Management could Prove Effective if Visibility in the Supply Chain Increases
4.7 Risk Management in Pharmaceutical Supply Chain Management
4.8 Radio Frequency Identification Technology to Play an Important Role in Improving Performance Visibility of the Pharmaceutical Supply Chain

5 Pharmaceutical Supply Chain in the US – Supply Chain Models
5.1 Pharmaceutical Supply Chain Models
5.1.1 Traditional Wholesaler Model
5.1.2 Limited Distribution Model or Specialty Pharmacy Distribution Model
5.1.3 Direct Distribution Model
5.2 Steps to Rationalize Existing Supply Chain
5.3 Cold-chain Storages to Play Critical Role in Supply Chain Management
5.4 Case Study - Implementing Lean Six Sigma to Revamp Pharmaceutical Company Performance

6 Pharmaceutical Supply Chain in the US – Securing a Supply Chain
6.1 Food and Drug Administration’s Role in Addressing Counterfeiting Issues
6.1.1 Case Study: How Counterfeits were Identified at the Border
6.1.2 Case Study: Wholesale Distributor Involved in Diversion Schemes
6.1.3 Case Study: Pharmacies and Pharmacist Involved in Drug Diversion of Samples
6.2 Counterfeiting
6.2.1 Case Study: Fake Cases of Cancer Drug Avastin Raises Issues of Secured Supply Chain Management
6.3 New Technologies Affecting the Performance of the Supply Chain
6.3.1 E-pedigree Track-and-trace Systems
6.3.2 California E-pedigree Implementation Model
6.3.3 Automation of Reports and Consolidated Orders System Reporting
6.3.4 Unique Device Identification for Improving the Traceability of Medical Devices
6.3.5 Radio Frequency Identification, Electronic Product Codes and Physical Mark up Language a Tested Anti-counterfeit Technology
6.4 Anti-counterfeiting Technology Classification
6.5 Overt Technology
6.5.1 Holograms/Diffractive Optical Elements
6.5.2 Optical Variable Device
6.5.3 Sequential Product Numbering
6.5.4 Security Graphics
6.5.5 Product Marking
6.5.6 Color-shifting Security Inks and Films
6.5.7 Film Wrappers
6.5.8 Shrink Seals and Bands
6.5.9 Breakable Caps
6.5.10 Sealed Tubes
6.6 Covet Technologies
6.6.1 Invisible Printing and Watermarks
6.6.2 Hidden Marks and Printing
6.7 Forensic Markers
6.7.1 Chemical Taggants
6.7.2 DNA Fragments
6.7.3 Micro-particle Taggants (Nanotaggants)
6.7.4 Isotope Ratio
6.8 Mass Serialization/Track-and-trace Technologies
6.8.2 Anti-counterfeiting Technologies and their Impact on Pharmaceutical Companies
6.9 Case Study: Sproxil to Benefit from Mobile Technology
6.10 Top Anti-counterfeiting Companies and their Innovative Technologies
6.10.1 Reed-Lane, Inc
6.10.2 Cortegra Group Inc
6.10.3 Nanolnk Inc
6.10.4 TraceLink Inc
6.10.5 Axway
6.10.6 Innovatum Inc
6.10.7 Vetter Pharma International GmbH

7 Pharmaceutical Supply Chain in the US – Legislative Specifications of Pharmaceutical Traceability Enhancement Code Act
7.1 Title l: Immediate Provisions to Enhance Patient Safety
7.2 Title ll: Development of RxTEC System
7.3 Title lll: Enhanced FDA and State Authorities
7.4 Title lV: RxTEC System Assessment
7.5 Title V: Uniform National Policy

8 Pharmaceutical Supply Chain in the US – Wholesale Sector
8.1 Market Leaders in the Wholesale Sector
8.2 Trends Seen Across the US Wholesale Industry
8.3 Prescription Drug Marketing Act of 1987
8.4 Market Share of Wholesalers
8.5 McKesson
8.5.1 Company Profile
8.6 AmerisourceBergen
8.6.1 Company Profile
8.7 Cardinal Health Inc
8.7.1 Company Profile

9 Pharmaceutical Supply Chain in the US – Pharmacy Sector
9.1 The US Pharmacy Sector
9.2 Market Share of Different Channels in the US Pharmaceutical Supply Chain
9.3 Market Share of Top Three Chain Drug Stores in the US

10 Pharmaceutical Supply Chain in the US – Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Bibliography
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Primary Research
10.4.4 Expert Panel Validation
10.5 Contact Us
10.6 Disclaimer

List of Tables


Table 1: Pharmaceutical Supply Chain in the US, Storage and Handling Regimes of Blockbuster Products, 2012 25
Table 2: Pharmaceutical Supply Chain in the US, Advantages and Disadvantages of Overt Features, 2012 36
Table 3: Pharmaceutical Supply Chain in the US, Advantages and Disadvantages of Covert Features, 2012 37
Table 4: Pharmaceutical Supply Chain in the US, Advantages and Disadvantages of Forensic Markers 38
Table 5: Pharmaceutical Supply Chain in the US, Advantages and Disadvantages of Track-and-trace Technologies, 2012 39

List of Figures


Figure 1: Pharmaceutical Supply Chain in the US, Evolution of Supply Chain Management, 2011 11
Figure 2: Pharmaceutical Supply Chain in the US, Implementation of Lean Supply Chain Management, 2011 12
Figure 3: Pharmaceutical Supply Chain in the US, Key Uncertainties Faced by Manufacturers, 2012 14
Figure 4: Pharmaceutical Supply Chain in the US, Number of Drug Callbacks, 2006-2011 16
Figure 5: Pharmaceutical Supply Chain in the US, Impact of Vioxx Withdrawal on Mercks Share Prices, January 2003December 2005 17
Figure 6: Pharmaceutical Supply Chain in the US, Risk Management Benefits, 2012 18
Figure 7: Pharmaceutical Supply Chain in the US, Risk Evaluation Procedure, 2012 19
Figure 8: Pharmaceutical Supply Chain in the US, Working of Radio Frequency Identification Technology, 2012 20
Figure 9: Pharmaceutical Supply Chain in the US, Structure of a Traditional Distribution Channel, 2012 21
Figure 10: Pharmaceutical Supply Chain in the US, Structure of a Limited Distribution Channel, 2012 22
Figure 11: Pharmaceutical Supply Chain in the US, Structure of a Direct-to-pharmacy Distribution Channel, 2011 23
Figure 12: Pharmaceutical Supply Chain in the US, Cold-chain Storage Forecast, $bn, 2011-2016 26
Figure 13: Pharmaceutical Supply Chain in the US, Counterfeit Drugs Identified, 2011 27
Figure 14: Pharmaceutical Supply Chain in the US, Wholesale Distributor Involved in Diversion Schemes, 2011 28
Figure 15: Pharmaceutical Supply Chain in the US, Pharmacies and Pharmacist Involved in Drug Diversion of Samples, 2011 29
Figure 16: Pharmaceutical Supply Chain in the US, Types of Trades Associated with Suspected Counterfeits, (%), 2011 30
Figure 17: Pharmaceutical Supply Chain in the US, Counterfeit Avastin Case Study, 2012 31
Figure 18: Pharmaceutical Supply Chain in the US, E-pedigree in a Pharmaceutical Supply Chain, 2012 32
Figure 19: Pharmaceutical Supply Chain in the US, Paper-based Pedigree in a Pharmaceutical Supply Chain, 2011 33
Figure 20: Pharmaceutical Supply Chain in the US, California E-pedigree Implementation Model, The US, 2012 34
Figure 21: Pharmaceutical Supply Chain in the US, Classification of Anti-counterfeit Technologies, 2012 35
Figure 22: Pharmaceutical Supply Chain in the US, Platform for Protecting Pharmaceutical Value Chain, 2012 40
Figure 23: Pharmaceutical Supply Chain in the US, Company Overview, Reed-Lane Inc, 2012 41
Figure 24: Pharmaceutical Supply Chain in the US, Company Overview, Cortegra Group Inc, 2012 42
Figure 25: Pharmaceutical Supply Chain in the US, Company Overview, NanoInk Inc, 2012 43
Figure 26: Pharmaceutical Supply Chain in the US, Company Overview, TraceLink, 2012 44
Figure 27: Pharmaceutical Supply Chain in the US, Company Overview, Axway, 2012 45
Figure 28: Pharmaceutical Supply Chain in the US, Company Overview, Innovatum Inc, 2012 46
Figure 29: Pharmaceutical Supply Chain in the US, Company Overview, Vetter Pharma International GmbH, 2012 47
Figure 30: Pharmaceutical Supply Chain in the US, Market Share of Wholesalers, (%), 2011 50
Figure 31: Pharmaceutical Supply Chain in the US, Company Profile, McKesson, 2011 51
Figure 32: Pharmaceutical Supply Chain in the US, Company Profile, AmerisourceBergen, 2011 52
Figure 33: Pharmaceutical Supply Chain in the US, Company Profile, Cardinal Health Inc, 2011 53
Figure 34: Pharmaceutical Supply Chain in the US, Market Share of Different Prescription-dispensing Channels, (%), 2011 54
Figure 35: Pharmaceutical Supply Chain in the US, Market Share of Top Three Chain Drug Stores, 2012 55

Upcoming Reports:

Bath And Shower Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Product innovations and use of nature-based ingredients in bath and shower products is driving the growth of this market. Consumers are focusing on buying nature-based products rather than chemical-based products. Many new manufacturers are emerging in the bath and shower industry as this market is creating new growth opportunities with new products development, packaging innovations, lifestyle influences, and distribution or pricing issues. The skin care market is posing the biggest challenge to the growth of the bath and shower industry as this industry is catching consumer...
Mens Health Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Men’s health therapeutics are used for males to treat and correct the diseases and disorders specific to androgens. Such therapeutics have garnered attention in recent times because of the health problems as a result of changes in hormones level.A rise in average age of men is observed globally which further results into increase in number of males with declined testosterone levels. The declined level of this hormone is major cause of men health issues and therefore, the global market for men’s health therapeutics is expected to grow with the increasing life expectancy and...
Industrial Clay Market - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecast, 2013 - 2019
By - Transparency Market Research
Clay is a type of soil which is made up of one or more minerals and traces of metal oxides and organic matter. Minerals used for industrial purposes are called industrial clays. Minerals such as kaolin, bentonite and palygorskite-sepiolite among others are included in industrial clays. These minerals do not possess expansion or shrinkage and remain hard at high temperatures. They offer services to industries such as ceramics, paints, rubbers, catalysts, refractories and cement among others. The increasing demand of these industrial clays in ceramics for various applications such as...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Private Schools Have Higher Male Teaching Staff Than State Schools: Report
Oct 22, 2014  
Private and state education has always been a matter of debate across the UK. A recent study has shown that when it comes to teaching employment options, the difference between state-run and private education in terms of gender balance is absolutely clear.  A report by the Independent Schools Council (ISC) shows that while women dominate both the education medium, the number of...
Abbots First Australian Renewable Energy Deal Rejected
Oct 22, 2014  
The Abbot government’s initial deal for a renewable energy plan has been immediately rejected by the clean energy industry and Labor. The negotiations are about a bipartisan agreement regarding the future of the Australian renewable energy target. The Labor party rejected the first plan as being a job-killer before it was even announced. The plan, they said, would protect solar...
Chemical Production in Europe Flatlines in First Seven Months of 2014
Oct 21, 2014  
The recently published report by European Chemical Industry Council (Cefic) shows overall chemical production in Europe has flatlined in first seven months of this year. Though the initial four months showed a positive trend, the production volumes dropped in July 2014 and in the following months as well. The contraction in output in the three consecutive months has nullified the upward trend...
Actavis to Compete for Omega Pharma
Oct 20, 2014  
Actavic Plc has declared that it will become one of the bidders for the Omega Pharma NV deal, as the United States based drug maker keeps searching for more takeovers. Actavis will be competing against Boehringer Ingelheim GmbH, Sanofi and Perrigi Co. for Omega Pharma. Actavis places themselves as a potential suitor along with quarry in a multitude of potential pharma combinations....
Sale of iPhone Fuels UKs s
Oct 20, 2014  
With the sale of Apple Inc.’s latest smartphone, consumer expenditure on electronics has registered a three-year high this September. The new iPhone 6 and iPhone 6 Plus were launched in the U.K. on September 19 and buyers from across the country raced to purchase the newest smartphone. Both these smartphones are so far the fastest selling Apple products with a sale of over 10 million...